What's in Grifols Therapeutics LLC's pipeline?

Grifols Therapeutics LLC has 16 drugs in our index: 6 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Grifols Therapeutics LLC's portfolio?

Top competitors by shared drug class: CSL Behring, Baxalta now part of Shire, Bio Products Laboratory, Biotest, Grifols Biologicals, LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/grifols-therapeutics-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Grifols Therapeutics LLC — Portfolio Competitive Intelligence Brief

Grifols Therapeutics LLC pipeline: 6 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 4 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Immune Globulin (Human)	Immune Globulin (Human)	marketed	Immunoglobulin replacement therapy	Multiple pathogenic antigens and pathogens (non-specific)	Immunology
Xembify	Xembify	marketed			Other
Diphtheria-Tetanus Toxoids Adsorbed	Diphtheria-Tetanus Toxoids Adsorbed	marketed
IGSC 20%	IGSC 20%	marketed
Prolastin-C	Prolastin-C	marketed	Alpha-1 protease inhibitor (augmentation therapy)	Alpha-1 antitrypsin (AAT); serine protease inhibitor	Pulmonology / Respiratory
GAMUNEX-C	GAMUNEX-C	marketed			Other
Alpha-1 MP	Alpha-1 MP	phase 3
Albutein 20%	Albutein 20%	phase 3
IGIV-C 10%	IGIV-C 10%	phase 3	Intravenous immunoglobulin (IVIG)		Immunology
IVIG-PEG	IVIG-PEG	phase 3	Immunoglobulin replacement therapy	Fc receptors and complement system (via pooled human IgG)	Immunology

Therapeutic area mix

Immunology · 3
Other · 3
Pulmonology / Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CSL Behring · 2 shared drug classes
Baxalta now part of Shire · 2 shared drug classes
Bio Products Laboratory · 1 shared drug class
Biotest · 1 shared drug class
Grifols Biologicals, LLC · 1 shared drug class
CSL Limited · 1 shared drug class
Biopharma Plasma LLC · 1 shared drug class
ADMA Biologics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Grifols Therapeutics LLC:

Cite this brief

Drug Landscape (2026). Grifols Therapeutics LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grifols-therapeutics-llc. Accessed 2026-05-16.